HLX02
1 clinical trial
1 abstract
1 indication
Indication
Breast CancerAbstract
The efficacy and safety of trastuzumab biosimilar HLX02 compared with reference trastuzumab plus pertuzumab in combination with chemotherapy as the first-line treatment for HER2 positive metastatic breast cancer: A real-world study in China.Org: Peking University Cancer Hospital & Institute, Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China,
Clinical trial
Double-blind, Randomized, Multicenter, Phase III Clinical Study to Compare the Efficacy and to Evaluate the Safety and Immunogenicity of Trastuzumab Biosimilar HLX02 and EU-sourced Herceptin® in Previously Untreated HER2 Overexpressing Metastatic Breast CancerStatus: Completed, Estimated PCD: 2018-11-23